Sugi Predict

Sugi Predict / Compounds / SCHEMBL214389

SCHEMBL214389

SCHEMBL214389

CC(=CC=O)CCCC(C)CCCC(C)CCCC(C)C

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 3/20 0.61
▸ LMNA P02545 1/20 0.46
▸ BLM P54132 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ PDE4A P27815 1/20 0.44
▸ SNCA P37840 1/20 0.44
▸ PDE3A Q14432 1/20 0.44
▸ KDM1A O60341 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PTPN2 P17706 1/20 0.39
▸ CDC25B P30305 1/20 0.39
▸ PSEN1 P49768 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31211760 1.00 PTPN1 (0.61) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL214388 1.00 PTPN1 (0.61) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL10411568 1.00 PTPN1 (0.61) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL13277591 1.00 PTPN1 (0.61) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL13277590 1.00 PTPN1 (0.61) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL10411567 1.00 PTPN1 (0.61) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL1785861 0.92 PTPN1 (0.48) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL15822466 0.92 PTPN1 (0.48) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL1785863 0.92 PTPN1 (0.48) PTPN1LMNABLMPTGS1PDE4A
SCHEMBL11667347 0.91 PTPN1 (0.59) PTPN1LMNABLMPTGS1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9980937-B2 Therapeutic agent for Alzheimer's disease NAGASAKI UNIVERSITY (JP) 2018-05-29 — — US claimed
US-20170252318-A1 NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE NAGASAKI UNIVERSITY (JP) 2017-09-07 — — US claimed
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS INDIANA STATE UNIVERSITY 2006-12-28 — — US claimed
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations GHOSH SWAPAN K (US) 2005-07-21 — — US claimed
EP-0309340-B1 1,3,5-NONATRIENE DERIVATIVES, THEIR PREPARATION AND USE RHONE-POULENC SANTE (FR) 1991-05-29 — — EP claimed
US-11724996-B2 Synthesis of intermediates for the preparation of alpha-tocopherol DSM IP ASSETS B.V. (NL) 2023-08-15 — — US disclosed
US-11724996-B2 Synthesis of intermediates for the preparation of alpha-tocopherol DSM IP ASSETS B.V. (NL) 2023-08-15 — — US disclosed
EP-3652162-B1 NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL DSM IP ASSETS BV (NL) 2023-02-22 — — EP disclosed
US-20210300886-A1 SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL DSM IP ASSETS BV (NL) 2021-09-30 — — US disclosed
US-20200131145-A1 NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL DSM IP ASSETS B.V. (NL) 2020-04-30 — — US disclosed
CN-111065634-A Novel synthesis of intermediate for preparing α -tocopherol 帝斯曼知识产权资产管理有限公司 2020-04-24 — — CN disclosed
EP-2518040-B1 LOW-VISCOSITY LIQUID-CRYSTAL COMPOUND FARNEX INCORPORATED (JP) 2018-10-31 — — EP disclosed
US-8088395-B2 Phytol derived immunoadjuvants and their use in vaccine formulations INDIANA STATE UNIVERSITY (US) 2012-01-03 — — US disclosed
CN-101970594-A Functional substance releasing agent KAO CORP 2011-02-09 — — CN disclosed
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS INDIANA STATE UNIVERSITY 2006-12-28 — — US disclosed
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations GHOSH SWAPAN K (US) 2005-07-21 — — US disclosed
US-5236950-A Phytol and isophytol derivatives TOYAMA CHEMICAL CO., LTD. (JP) 1993-08-17 — — US disclosed
US-4876370-A 1,3,5-nonatriene derivatives, their preparation and their use RHONE-POULENC SANTE (FR) 1989-10-24 — — US disclosed
US-3994936-A Catalytic rearrangement HOFFMANN-LA ROCHE INC. (US) 1976-11-30 — — US disclosed
US-3981896-A CONVERSION OF ACETYLENIC ALCOHOLS TO ALDEHYDES AND KETONES HOFFMANN-LA ROCHE INC. (US) 1976-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300886-A1 SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL TTPA, DHPS, SQLE PTPN1 4639/4885LMNA 1425/4885BLM 3409/4885
US-20200131145-A1 NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL TTPA, VKORC1, SQLE PTPN1 4761/4885LMNA 1413/4885BLM 3636/4885
US-20170252318-A1 NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE PSEN2, BACE1, PSEN1 PTPN1 4740/4885LMNA 615/4885BLM 4800/4885
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations CD47, TSG101, LY96 PTPN1 475/4885LMNA 3976/4885BLM 1167/4885
US-11724996-B2 Synthesis of intermediates for the preparation of alpha-tocopherol TTPA, DHPS, SQLE PTPN1 4639/4885LMNA 1425/4885BLM 3409/4885
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS CD47, LY96, CD4 PTPN1 317/4885LMNA 3674/4885BLM 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.